发明名称 |
Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE |
摘要 |
Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.
|
申请公布号 |
US2010150953(A1) |
申请公布日期 |
2010.06.17 |
申请号 |
US20090635656 |
申请日期 |
2009.12.10 |
申请人 |
HUMPHREYS ROBERT;XU MINZHEN |
发明人 |
HUMPHREYS ROBERT;XU MINZHEN |
分类号 |
A61K39/385;A61P35/00 |
主分类号 |
A61K39/385 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|